Literature DB >> 23318126

Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis.

Peter L Foley1, Hanna M Vesterinen, Barry J Laird, Emily S Sena, Lesley A Colvin, Siddharthan Chandran, Malcolm R MacLeod, Marie T Fallon.   

Abstract

The prevalence, associations, and natural history of pain in multiple sclerosis (MS) are poorly understood. The objective of this work was to study the prevalence of pain syndromes in MS both cross-sectionally, and longitudinally during the MS disease course. We systematically identified prospective studies detailing pain prevalence in definite MS. We used pooled prevalence estimates, explored heterogeneity using meta-regression, and analysed prevalence during the disease course using both estimates at disease milestones and longitudinal studies. Twenty-eight articles (7101 subjects) describing overall pain, or pain syndromes, met inclusion criteria. Pooled overall pain prevalence (17 studies, 5319 subjects) was 63% (95% confidence interval [CI] 55-70%). Marked heterogeneity in this estimate was not significantly explained by selected study design variables (use of outpatient sample, timeframe prior to study over which pain was assessed) or sample demographic variables (mean Expanded Disability Status Scale, mean disease duration, proportion of female sex, and proportion with progressive MS). We quantified prevalence of headache (43%; 95% CI 33-52%), neuropathic extremity pain (26%; 95% CI 7-53%), back pain (20%; 95% CI 13-28%), painful spasms (15%; 95% CI 8.5-23%), Lhermitte sign (16%; 95% CI 10-25%), and trigeminal neuralgia (3.8%; 95% CI 2-6%) in included studies. Prevalence of pain at MS disease milestones (prior to onset, at onset, and at relapse) and during longitudinal follow-up was poorly described. Pain is common in MS, as are specific pain syndromes. The clinical associations and natural history of pain in MS require clarification. Future study could be enhanced by standardised study design.
Copyright © 2012 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23318126     DOI: 10.1016/j.pain.2012.12.002

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  62 in total

1.  Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.

Authors:  David Bargiela; Matthew T Bianchi; M Brandon Westover; Lori B Chibnik; Brian C Healy; Philip L De Jager; Zongqi Xia
Journal:  Neurology       Date:  2017-01-13       Impact factor: 9.910

2.  Prolonged stimulation of a brainstem raphe region attenuates experimental autoimmune encephalomyelitis.

Authors:  Pernille M Madsen; Stephanie S Sloley; Alberto A Vitores; Melissa M Carballosa-Gautam; Roberta Brambilla; Ian D Hentall
Journal:  Neuroscience       Date:  2017-01-29       Impact factor: 3.590

3.  Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.

Authors:  Claudio Solaro; M Cella; Alessio Signori; Vittorio Martinelli; Marta Radaelli; D Centonze; F Sica; M G Grasso; A Clemenzi; S Bonavita; S Esposito; F Patti; E D'Amico; G Cruccu; A Truini
Journal:  J Neurol       Date:  2018-02-05       Impact factor: 4.849

4.  Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

Authors:  Weisi Fu; Bradley K Taylor
Journal:  Neurosci Lett       Date:  2015-04-03       Impact factor: 3.046

5.  Systematic assessment and characterization of chronic pain in multiple sclerosis patients.

Authors:  Diana Ferraro; Domenico Plantone; Franca Morselli; Giulia Dallari; Anna M Simone; Francesca Vitetta; Patrizia Sola; Guido Primiano; Viviana Nociti; Matteo Pardini; Massimiliano Mirabella; Catello Vollono
Journal:  Neurol Sci       Date:  2017-12-09       Impact factor: 3.307

Review 6.  Botulinum Toxin Treatment in Multiple Sclerosis-a Review.

Authors:  Yasaman Safarpour; Tahereh Mousavi; Bahman Jabbari
Journal:  Curr Treat Options Neurol       Date:  2017-08-17       Impact factor: 3.598

Review 7.  Cannabinoids for Treatment of MS Symptoms: State of the Evidence.

Authors:  Jessica Rice; Michelle Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-19       Impact factor: 5.081

8.  Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.

Authors:  Nicola S Orefice; Mireille Alhouayek; Antonio Carotenuto; Silvana Montella; Franscesco Barbato; Albert Comelli; Antonio Calignano; Giulio G Muccioli; Giuseppe Orefice
Journal:  Neurotherapeutics       Date:  2016-04       Impact factor: 7.620

9.  IL-1β Is Involved with the Generation of Pain in Experimental Autoimmune Encephalomyelitis.

Authors:  David Henrique Rodrigues; Bruno Pereira Leles; Vivian Vasconcelos Costa; Aline Silva Miranda; Daniel Cisalpino; Dawidson Assis Gomes; Danielle Glória de Souza; Antônio Lúcio Teixeira
Journal:  Mol Neurobiol       Date:  2015-11-28       Impact factor: 5.590

10.  Mechanisms and pharmacology of neuropathic pain in multiple sclerosis.

Authors:  T Iannitti; B J Kerr; B K Taylor
Journal:  Curr Top Behav Neurosci       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.